19.01.2021 Carl Zeiss Meditec AG  DE0005313704

DGAP-Adhoc: Carl Zeiss Meditec AG achieves increase in profit in first quarter 2020/21


 

DGAP-Ad-hoc: Carl Zeiss Meditec AG / Key word(s): Quarter Results
Carl Zeiss Meditec AG achieves increase in profit in first quarter 2020/21

19-Jan-2021 / 09:54 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Carl Zeiss Meditec AG achieves increase in profit in first quarter 2020/21
Jena, January 19, 2021

Carl Zeiss Meditec AG (ISIN: DE0005313704) has achieved revenue of EUR 368.9 million in the first quarter of fiscal year 2020/21 (previous year: EUR 369.7 million). This corresponds to a revenue development of -0.2% vs. the past year (after adjustment for currency effects[1]: +2.6%).

Earnings before interest and taxes (EBIT)[2] amounted to EUR 73.4 million in the first quarter of fiscal year 2020/21 (previous year: EUR 56.8 million). EBIT margin (EBIT / revenue) was 19.9% (previous year 15.4%). EBIT development benefitted in part from lower sales and marketing expenses compared to the previous year's period. In addition, EBIT includes a one-time gain from the sale of a property in the amount of around EUR 2.4 million in the current period.

Earnings per share (EPS)[3] amounted to EUR 0.52 (previous year: EUR 0.43).

Full results for the first quarter 2020/21 will be published on February 8, 2021.

During the further course of fiscal year 2020/21, the company expects the recovery in revenue and EBIT to continue compared to the previous year, which had seen a marked impact from the COVID-19 pandemic.
 
 

 

Contact for investors and press
Sebastian Frericks
Head of Investor Relations
Carl Zeiss Meditec AG
Tel.: +49 3641 220-116
E-Mail: [email protected]

 

[1] Currency-adjusted revenue growth is determined by weighing sales in the comparative period with current instead of actual historical exchange rates.
[2] Earnings before interest and taxes (also operating profit, EBIT) refers to a key earnings figure within the Carl Zeiss Meditec Group and is calculated in accordance with IFRS standards (see Annual Report 2019/20, p. 78 for reconciliation).
[3] Earnings per share (also EPS) refers to a key earnings figure within the Carl Zeiss Meditec Group and is calculated according to IFRS standards (see Annual Report 2019/20, p. 78 for reconciliation).


19-Jan-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Carl Zeiss Meditec AG
Göschwitzer Str. 51-52
07745 Jena, Germany
Germany
Phone: +49 (0)3641 220-0
Fax: +49 (0)3641 220-112
E-mail: [email protected]
Internet: www.zeiss.de/meditec-ag/ir
ISIN: DE0005313704
WKN: 531370
Indices: MDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1161506

 
End of Announcement DGAP News Service

1161506  19-Jan-2021 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1161506&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022e
Umsatzerlöse1 1.088,37 1.189,90 1.280,86 1.459,32 1.335,45 1.646,79 1.710,00
EBITDA1,2 174,56 205,07 228,41 313,03 237,98 435,20 407,50
EBITDA-Marge3 16,04 17,23 17,83 21,45 17,82 26,43 23,83
EBIT1,4 154,33 180,83 197,13 264,66 177,55 373,61 344,00
EBIT-Marge5 14,18 15,20 15,39 18,14 13,30 22,69 20,12
Jahresüberschuss1 99,97 135,78 126,23 160,58 123,42 237,52 221,00
Netto-Marge6 9,19 11,41 9,86 11,00 9,24 14,42 12,92
Cashflow1,7 111,77 37,73 187,21 219,63 178,53 362,66 0,00
Ergebnis je Aktie8 1,21 1,57 1,41 1,79 1,37 2,64 2,70
Dividende8 0,42 0,55 0,55 0,65 0,50 0,90 0,90
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2021 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Ernst & Young

INVESTOR-INFORMATIONEN
©boersengefluester.de
Carl Zeiss Meditec
WKN Kurs in € Einschätzung Börsenwert in Mio. €
531370 136,050 Halten 12.168,39
KGV 2023e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
43,89 31,92 1,39 89,21
KBV KCV KUV EV/EBITDA
7,34 33,55 7,39 25,80
Dividende '20 in € Dividende '21e in € Div.-Rendite '21e
in %
Hauptversammlung
0,50 0,90 0,66 30.03.2022
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
11.02.2022 13.05.2022 05.08.2022 09.12.2022
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
10,67% -5,37% -26,40% -30,16%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Carl Zeiss Meditec AG  ISIN: DE0005313704 können Sie bei DGAP abrufen


Medtech , 531370 , AFX , XETR:AFX